StreetInsider.com News Articles

Amgen (AMGN) PT Raised to $500 at Scotiabank

Tue, 29 Sep 2026 07:23:25 -0400

Scotiabank analyst Louis Chen raised the price target on Amgen (NASDAQ: AMGN) to $500.00 (from $450.00) while maintaining a Sector Outperform rating.

Canaccord Reiterates Hold Rating on Amgen (AMGN)

Wed, 23 Sep 2026 06:38:22 -0400

Canaccord analyst Gary Nachman reiterated a Hold rating and $384.00 price target on Amgen (NASDAQ: AMGN).

The analyst commented: "AMGN announced positive topline results from the first of two Ph3 trials of dazodalibep in moderate-to-severe Sjogren's disease (SjD), a solid win for its pipeline. Dazodalibep (potential first-in-class CD40L antagonist fusion protein) met the primary endpoint in the OASIZ 301 Ph3 trial that evaluated patients with SjD with moderate-to-severe systemic disease activity. It demonstrated a statistically significant and clinically meaningful improvement in change from baseline in ESSDAI at Week 48, with improvements observed as early as Week 4 and sustained through Week

Amgen (AMGN) PT Raised to $410 at Jefferies

Wed, 23 Sep 2026 05:27:52 -0400

Jefferies analyst Akash Tewari raised the price target on Amgen (NASDAQ: AMGN) to $410.00 (from $367.00) while maintaining a Hold rating.

The analyst comments "Dazodalibep (AMGN's CD40L antagonist) Ph3 in mod-severe systemic Sjögren's disease hit. We'll note: 1) Dazo improved ESSDAI as early as wk4, vs. the wk12-16 separation seen in IAN's NEPTUNUS Ph3s, 2) potentially better safety/tolerability vs. other data sets in the space. Based on the current data, we are getting incrementally more positive going into the OASIZ-303 trial (Dazo in symptomatic SjD pop; expt'ed in Q4'26).Dazo PS: ~$1Bn → $4.5Bn. PT: $367 → $410."

Amgen (AMGN) PT Raised to $410 at Jefferies

Wed, 23 Sep 2026 05:27:52 -0400

Jefferies analyst Akash Tewari raised the price target on Amgen (NASDAQ: AMGN) to $410.00 (from $367.00) while maintaining a Hold rating.

Oppenheimer Reiterates Outperform Rating on Amgen (AMGN)

Wed, 23 Sep 2026 05:24:23 -0400

Oppenheimer analyst Jay Olson reiterated an Outperform rating and $450.00 price target on Amgen (NASDAQ: AMGN).

The analyst comments "AMGN shares were up 4.3% on 09/22 (vs. NBI: +1.7%) as the company announced positive results from the first Ph3 study, OASIZ 301, evaluating dazodalibep (DAZ) in patients with systemic Sjögren's disease. We view the update as encouraging given the hard-to-treat nature of the disease and believe it provides a favorable setup for the upcoming OASIZ 303 study (expected to complete in 4Q) in a somewhat different patient population, which could ultimately provide important differentiation for DAZ vs. other emerging therapies including

Amgen's dazodalibep meets primary endpoint in Sjögren's Phase 3 trial

Tue, 22 Sep 2026 09:02:19 -0400

Amgen (NASDAQ: AMGN) announced that its Phase 3 OASIZ 301 study evaluating dazodalibep in adults with moderate-to-severe systemic Sjögren's disease met its primary endpoint, according to a company press release.

The study measured change from baseline in the EULAR Sjögren's Syndrome Disease Activity Index (ESSDAI) score at Week 48, a validated tool used to assess systemic disease activity across organ systems. The trial enrolled approximately 621 patients with an ESSDAI score of five or higher. Improvements in ESSDAI were observed as early as Week 4 and were sustained through Week 48.

Dazodalibep is described as a CD40L antagonist fusion protein designed to

AMGEN ANNOUNCES POSITIVE TOPLINE PHASE 3 RESULTS FOR DAZODALIBEP IN MODERATE-TO-SEVERE SYSTEMIC SJÖGREN'S DISEASE

Tue, 22 Sep 2026 09:00:00 -0400

Dazodalibep Demonstrated Statistically Significant and Clinically Meaningful Improvement in Systemic Disease Activity

Results Support the Potential for a New, Highly Differentiated Treatment Option for People Living With a Debilitating Autoimmune Disease

THOUSAND OAKS, Calif., Sept. 22, 2026 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced positive

AMGEN ANNOUNCES POSITIVE TOPLINE PHASE 3 RESULTS FOR DAZODALIBEP IN MODERATE-TO-SEVERE SYSTEMIC SJÖGREN'S DISEASE

Tue, 22 Sep 2026 09:00:00 -0400

Dazodalibep Demonstrated Statistically Significant and Clinically Meaningful Improvement in Systemic Disease Activity

Results Support the Potential for a New, Highly Differentiated Treatment Option for People Living With a Debilitating Autoimmune Disease

THOUSAND OAKS, Calif., Sept. 22, 2026 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced positive

Roche obesity drug shows 15.5% weight loss in diabetes trial

Tue, 22 Sep 2026 07:26:17 -0400

Investing.com -- Swiss drugmaker Roche announced Tuesday that its experimental obesity treatment helped patients with type 2 diabetes reduce blood sugar levels and lose an average 15.5% of their body weight in a mid-stage trial.

The company is competing with AstraZeneca and Amgen to enter the obesity drug market currently dominated by Eli Lilly and Novo Nordisk.

The experimental drug, enicepatide, is a once-weekly injection that mimics GLP-1 and GIP hormones to reduce appetite and regulate blood sugar.

Patients who received 24 milligrams of enicepatide, the highest dose, saw reductions in HbA1c levels at 48 weeks, meeting the two main goals of the

Roche obesity drug shows 15.5% weight loss in diabetes trial

Tue, 22 Sep 2026 07:26:17 -0400

The company is competing with AstraZeneca and Amgen to enter the obesity drug market currently dominated by Eli Lilly and Novo Nordisk.

The experimental drug, enicepatide, is a once-weekly injection that mimics GLP-1 and GIP hormones to reduce appetite and regulate blood sugar.

Patients who received 24 milligrams of enicepatide, the highest dose, saw reductions in HbA1c levels at 48 weeks, meeting the two main goals of the

Roche obesity drug shows 15.5% weight loss in diabetes trial

Tue, 22 Sep 2026 07:26:17 -0400

The company is competing with AstraZeneca and Amgen to enter the obesity drug market currently dominated by Eli Lilly and Novo Nordisk.

The experimental drug, enicepatide, is a once-weekly injection that mimics GLP-1 and GIP hormones to reduce appetite and regulate blood sugar.

Patients who received 24 milligrams of enicepatide, the highest dose, saw reductions in HbA1c levels at 48 weeks, meeting the two main goals of the

Roche obesity drug shows 15.5% weight loss in diabetes trial

Tue, 22 Sep 2026 07:26:17 -0400

The company is competing with AstraZeneca and Amgen to enter the obesity drug market currently dominated by Eli Lilly and Novo Nordisk.

The experimental drug, enicepatide, is a once-weekly injection that mimics GLP-1 and GIP hormones to reduce appetite and regulate blood sugar.

Patients who received 24 milligrams of enicepatide, the highest dose, saw reductions in HbA1c levels at 48 weeks, meeting the two main goals of the

Amgen (AMGN) PT Lowered to $430 at UBS

Thu, 17 Sep 2026 08:28:37 -0400

UBS analyst Michael Yee lowered the price target on Amgen (NASDAQ: AMGN) to $430.00 (from $440.00) while maintaining a Buy rating.

The analyst commented, "We reduce our PT to $430 from $440, applying a ~17x multiple (vs. ~18x previously) to our 2027E EPS of $24.91, reflecting a lower PoS for olpasiran following NVS' pelacarsen Lp(a) missing the MACE-4 endpoint in the Phase III HORIZON CVOT."

Amgen (AMGN) PT Lowered to $430 at UBS

Thu, 17 Sep 2026 08:28:37 -0400

UBS analyst Michael Yee lowered the price target on Amgen (NASDAQ: AMGN) to $430.00 (from $440.00) while maintaining a Buy rating.

FDA cuts monitoring time for Amgen's Imdelltra initial doses

Mon, 14 Sep 2026 09:01:28 -0400

Amgen (NASDAQ: AMGN) said the U.S. Food and Drug Administration approved an update to the prescribing information for Imdelltra (tarlatamab-dlle) that reduces the recommended monitoring period for the first two doses of the treatment.

Under the updated label, patients receiving Imdelltra must now be monitored for 6 to 8 hours from the start of their first two infusions, down from the previously required 22 to 24 hours. Patients will also receive a follow-up assessment, including vital signs checks, the day after each of those first two doses. Monitoring requirements for subsequent doses remain unchanged.

Imdelltra is indicated for adult patients with extensive-stage

FDA APPROVES REDUCED MONITORING TIME FOR FIRST TWO DOSES OF IMDELLTRA®

Mon, 14 Sep 2026 09:00:00 -0400

Update Supports Broader Access to IMDELLTRA in Community Settings for People Living with Extensive-Stage Small Cell Lung Cancer

THOUSAND OAKS, Calif., Sept. 14, 2026 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) approved an update to the IMDELLTRA^® (tarlatamab-dlle) Prescribing Information that substantially reduces the recommended monitoring time for the first

FDA APPROVES REDUCED MONITORING TIME FOR FIRST TWO DOSES OF IMDELLTRA®

Mon, 14 Sep 2026 09:00:00 -0400

Update Supports Broader Access to IMDELLTRA in Community Settings for People Living with Extensive-Stage Small Cell Lung Cancer

HSBC lifts Novartis, downgrades Amgen in biopharma catalyst review

Thu, 10 Sep 2026 06:38:02 -0400

Investing.com -- HSBC adjusted ratings and target prices across its biopharma coverage, citing "a lower sector additional risk premium" following a rally in the second quarter of 2026.

Analysts led by Rajesh Kumar said pharma multiples are at a decade high, and further outperformance will require a medium-term growth upgrade rather than "defensive positioning in out of AI/Tech rotation." The team mapped and scored more than 100 clinical catalysts through 2027 across its coverage universe.

"The next 12 months look less like ’a rising tide lifts all boats’ and more like bottom-up stock picking," the analysts wrote, adding that catalyst quality, franchise

HSBC lifts Novartis, downgrades Amgen in biopharma catalyst review

Thu, 10 Sep 2026 06:38:02 -0400

Investing.com -- HSBC adjusted ratings and target prices across its biopharma coverage, citing "a lower sector additional risk premium" following a rally in the second quarter of 2026.

"The next 12 months look less like ’a rising tide lifts all boats’ and more like bottom-up stock picking," the analysts wrote, adding that catalyst quality, franchise

HSBC Downgrades Amgen (AMGN) to Hold

Thu, 10 Sep 2026 03:21:32 -0400

HSBC analyst Morten Herholdt downgraded Amgen (NASDAQ: AMGN) from Buy to Hold with a price target of $425.00 (from $445.00).

The analyst comments: “We downgrade Amgen to Hold from Buy as the shares have re-rated on strong execution and positive estimate revisions, leaving the stock trading around fair value and close to our target price. Our long-term thesis is unchanged that Amgen can work through the patent cliff via rare disease exposure, new launches and a growing biosimilar portfolio, but we see limited near-term upside. With steady patent expiries likely to cap growth to low single digits and major pipeline value

HSBC Downgrades Amgen (AMGN) to Hold

Thu, 10 Sep 2026 03:21:32 -0400

HSBC analyst Morten Herholdt downgraded Amgen (NASDAQ: AMGN) from Buy to Hold with a price target of $425.00 (from $445.00).

AMGEN TO PRESENT AT THE MORGAN STANLEY 24TH ANNUAL GLOBAL HEALTHCARE CONFERENCE

Wed, 09 Sep 2026 16:01:00 -0400

THOUSAND OAKS, Calif., Sept. 9, 2026 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will present at the Morgan Stanley 24^th Annual Global Healthcare Conference at 11:30 a.m. ET on Tuesday, September 15, 2026. Jay Bradner, executive vice president, Research and Development, Artificial Intelligence and Data at Amgen, and Thomas Dittrich, executive vice president and chief financial officer at Amgen, will present at the conference. The webcast will be broadcast over the internet simultaneously and will be available to members of the news media, investors and the general public.

The webcast, as with other selected presentations regarding developments in Amgen's business given by management at certain investor and

AMGEN TO PRESENT AT THE MORGAN STANLEY 24TH ANNUAL GLOBAL HEALTHCARE CONFERENCE

Wed, 09 Sep 2026 16:01:00 -0400

The webcast, as with other selected presentations regarding developments in Amgen's business given by management at certain investor and

BMO lowers Amgen, BioNTech to Market Perform as risk-reward shifts

Tue, 08 Sep 2026 07:22:58 -0400

Investing.com -- BMO Capital Markets downgraded Amgen and BioNTech to Market Perform from Outperform on Tuesday, citing limited near-term upside and more balanced risk-reward for biopharma companies.

BMO analyst Evan Seigerman cut Amgen’s rating while maintaining a price target of $450. Seigerman said commercial execution is now the base case for the stock, with shares up 34% year-to-date, outperforming the broader S&P 500 and the NYSE Arca Pharmaceutical indexes.

Amgen continues to face significant loss-of-exclusivity headwinds, Seigerman said, with pressure visible on Prolia/XGEVA, Enbrel, Otezla and Kyprolis. He said the company’s obesity drug MariTide "offers a potentially differentiated

BMO lowers Amgen, BioNTech to Market Perform as risk-reward shifts

Tue, 08 Sep 2026 07:22:58 -0400

Investing.com -- BMO Capital Markets downgraded Amgen and BioNTech to Market Perform from Outperform on Tuesday, citing limited near-term upside and more balanced risk-reward for biopharma companies.